Note from CCHR: Due to the severe adverse reactions from psychiatric drugs finally becoming a matter of public knowledge, as well as studies proving psychiatric drugs are no more effective than placebo, the psychiatric drug lords have now come up with a more overtly drug dealer approach; prescribe patients lysergic acid diethylamide (LSD), Ketamine (An animal tranquilizer known as Special K on the the street) and psilocybin (mushrooms).

Medscape
By Deborah Brauser
August 25, 2010

Low doses of psychedelic drugs, including lysergic acid diethylamide (LSD), ketamine, and psilocybin, may reduce clinical symptoms in patients with depression, anxiety, obsession-compulsive disorders (OCDs), and chronic pain, without inducing depersonalization or hallucinations, according to a new Perspectives article published online August 18 in Nature Reviews Neuroscience.

The study authors note that this may be due to the drugs’ effect on patients’ altered brain circuits and neurotransmitter systems, including serotonin and glutamate systems, according to recent neuroimaging data.

“These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity,” write Franz X. Vollenweider, MD, director of the Neuropsychopharmacology and Brain Imaging Research Unit at the University Hospital of Psychiatry in Zurich, Switzerland, and colleagues.

“These are serious, debilitating, life-shortening illnesses, and as the currently available treatments have high failure rates, psychedelics might offer alternative treatment strategies that could improve the well-being of patients and the associated economic burden on [them] and society,” they add.

Recent Research

Although research on psychedelics has been restricted for almost 40 years because of the drugs’ negative connotations, “recent advances in our understanding of the neurobiology of psychedelics” have led to renewed interest, write the study authors.

Read entire article here:  http://www.medscape.com/viewarticle/727438

« Return to news items

News Feed

Related Posts

• Leading psychologist says antidepressants no better than placebo—the difference is no suicidal side effects with placebo (1)
• Mental health services have become increasingly dominated by psychiatry’s ”medical model” (0)
• The Small Group of Thoughtful, Committed Citizens Has Been Drugged (0)
• Dealing With Depression Naturally (0)
• 1 million misdiagnosed ADHD children for $80B drug industry (0)

Tags: Adverse reactions, altered brain circuits, animal tranquilizer, ketamine, lsd, lysergic acid diethylamide, mushrooms, Nature Reviews Neuroscience, Neuropsychopharmacology and Brain Imaging Research Unit, neurotransmitter, placebo, psilocybin, psychedelic drugs, psychedelics, psychiatric drugs, serotonin, Special K, Switzerland, University Hospital of Psychiatry in Zurich

This entry was posted on Wednesday, August 25th, 2010 at 6:06 pm and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.